Local tumor control in radiation therapy of cancers in the head and neck

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 5, 1996, Pages 469-477

  Levendag, Peter C ^a   Nowak, Peter J C M ^a   Van der Sangen, Maurice J C ^a   Jansen, Peter P ^a   Eijkenboom, Wilhelmina M H ^a   Planting, André S Th ^a   Meeuwis, Cees A ^a   Van Putten, Wim L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Continuous course; Dose response; Head and neck; Local control; Overall treatment time; Radiation therapy; Split course

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; DOSE RESPONSE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NASOPHARYNX CANCER; OROPHARYNX CANCER; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES;

EID: 0029840698     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199610000-00009     Document Type: Article

References (33)

1. Peters LJ, Thames HD. Dose-response relationship for supraglottic laryngeal carcinoma. Int J Radiat Oncol Biol Phys 1983;9:421-2.
2. Terhaard CHJ, Karim ABMF, Hoogenraad WJ. Local control in T3 laryngeal cancer treated with radical radiotherapy, time dose relationship: the concept of NSD and LQ model. Int J Radiat Oncol Biol Phys 1991;20:1207-14.
3. van Putten WLJ, van der Sangen MJC, Hoekstra CJM, Levendag PC. Dose, fractionation and overall treatment time in radiation therapy - the effects on local control for cancer of the larynx. Radiother Oncol 1994;30:97-108.
4. Levendag PC, Ravasz LA, Terhaard CHJ, Hordijk GJ. T3 squamous cell carcinoma of the larynx treated by a split-course radiation protocol. A multiinstitutional study. Am J Clin Oncol 1993;16:509-18.
5. Hoekstra CJM, Levendag PC, van Putten WLJ. Squamous cell carcinoma of the supraglottic larynx without clinically detectable lymph node metastases: problem of local relapse and influence of overall treatment time. Int J Radiat Oncol Biol Phys 1990;18:13-21.
6. Bentzen SM, Johansen LV, Overgaard J, Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 1991;20:1197-206.
7. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother Oncol 1991;22:161-6.
8. Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 1989;16:831-43.
9. Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx. Part 2. Normal tissue responses: acute and late effects. Int J Radiat Oncol Biol Phys 1990;18:101-11.
10. Parsons JT, Bova FJ, Million RR. A reevaluation of split-course technique for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1980;6:1645-52.
11. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
12. Trott KR, Kummermehr J. What is known about tumor proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother Oncol 1985;3:1-9.
13. Tucker SL, Chan KS. The selection of patients for accelerated radiotherapy on the basis of tumor growth kinetics and intrinsic radiosensitivity. Radiother Oncol 1990;18:197-211.
14. Fowler JF. Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol 1992;2:16-21.
15. Begg AC, Hofland I, Van Glabbeke M. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin Radiat Oncol 1992;2:22-5.
16. Terhaard CHJ, Wiggenraad RG, Hordijk GJ, Ravasz LA. Regression after 50 Gy as a selection for therapy in advanced laryngeal cancer. Int J Radiat Oncol Biol Phys 1988;15:591-7.
17. Ensley JF, Jacobs JR, Weaver A. Correlation between response to cis-platinum combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54:811-4.
18. Pfister DG, Strong E, Harrison L. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer. J Clin Oncol 1991;9:850-9.
19. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1990;324:1685-90.
20. Sobil S, Rubin P, Keller B, Poulter C. Tumor persistence as a predictor of outcome after radiotherapy of head and neck cancers. Int J Radiat Oncol Biol Phys 1976;1:873-80.
21. Suit HD, Lindberg R, Fletcher GH. Prognostic significance of extent tumor regression at completion of radiation therapy. Radiology 1965;84:1100-7.
22. Tubiana M. Repopulation in human tumors - a biologic background for fractionation in radiotherapy. Acta Oncol 1988;27:83-8.
23. Rosenthal DI, Pistenmaa DA, Glatstein E. A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int J Radiat Oncol Biol Phys 1994;28:315-20.
24. Hermanek P, Sobin LH. TNM Classification of Malignant Tumours. Berlin: Springer-Verlag, 1987.
25. American Joint Committee on Cancer. Manual for Staging of Cancer. Philadelphia: Lippincott, 1988.
26. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187-220.
27. Berry G. The analysis of mortality by the subject-years method. Biometrics 1983;39:173-84.
28. Zidan J, Kuten A, Cohen Y. Multidrug chemotherapy using bleomycin, methotrexate and cisplatin combined with radical radiotherapy in advanced head and neck cancer. Cancer 1987;59:24-6.
29. Ervin TJ, Clark JR, Weichselbaum RR. An analysis of induction and adjuvant chemotherapy in the multi-disciplinary treatment of squamous cell carcinoma of the head and neck. J Clin Oncol 1987;5:10-20.
30. Stell PM, Rawson NS. Adjuvant chemotherapy in head and neck cancer. Br J Cancer 1990;61:779-87.
31. Denham JW, Abbott RL. Concurrent cisplatin, infusional fluorouracil, and conventional fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity. J Clin Oncol 1991;9:458-63.
32. Sanchiz F, Milla A, Torner J. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347-50.
33. Kallman RF. The importance of schedule and drug dose intensity in combinations of modalities. Int J Radiat Oncol Biol Phys 1994;28:761-71.